Oncology

Latest News

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com
Is a New Era of SCLC, LCNEC Treatments on the Horizon?

July 23rd 2025

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

Christine Pfaff, MBA, RPh | Image: LinkedIn
COA Welcomes Christine Pfaff, MBA, RPh, to Leadership Team

July 22nd 2025

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com
Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

July 22nd 2025

Cancer diagnosis financial strain | Image Credit: Maggie-sort.chatgpt.com
Cancer Diagnoses Bring Major Financial Burden for Privately Insured Adults

July 21st 2025

COVID-19 vaccine for patients with cancer. | Image Credit: Framestock - stock.adobe.com
COVID-19 Boosters Crucial for Patients With Cancer Despite Low Uptake

July 17th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 23rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 23rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Kazia Gains Orphan Designation for Investigational Glioblastoma Treatment
February 25th 2018

Kazia Gains Orphan Designation for Investigational Glioblastoma Treatment

Kelly Davio
Kazia Therapeutics Limited, an oncology-focused biotechnology company, announced on Friday that it has received the FDA’s Orphan Drug Designation for its investigational drug, GDC-0084, for the treatment of glioblastoma multiforme, the most aggressive form of primary brain cancer.
Site Logo
February 25th 2018

Future Shock: Embracing Disruption in the Immunotherapy Revolution

Joseph Alvarnas, MD
Dr Alvarnas is editor in chief and director of Value-Based Analytics at City of Hope, Duarte, California.
Study Finds Written Standardized Protocol Leads to Better Surgical Outcomes
February 24th 2018

Study Finds Written Standardized Protocol Leads to Better Surgical Outcomes

Samantha DiGrande
A study to be published in the Journal of the American College of Surgeons found that a safety-net hospital in Florida could perform an esophagectomy, a highly complex operation, with fewer complications and shorter hospital stays than the national average.
Podcast: This Week in Managed Care—Short-Term Health Plans and Other Health News
February 24th 2018

Podcast: This Week in Managed Care—Short-Term Health Plans and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors
February 24th 2018

Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors

Jaime Rosenberg
Recent study results showed larotrectinib was effective in patients with tropomyosin receptor kinase fusion-positive cancer, regardless of the age of the patient or the tumor type. In addition to implications for the treatment of genetic alterations across tumor types, these study results underscore the importance of molecular profiling of tumors, through which patients were identified for the studies, on ensuring precision medicine is used in practice while simultaneously providing a cost-effective tool.
This Week in Managed Care: February 23, 2018
February 23rd 2018

This Week in Managed Care: February 23, 2018

This week, the top managed care stories included the Trump administration proposed extending the duration of short-term health plans; a report found that CAR T-cell therapies are worth their high price tags; the new issue of Evidence-Based Oncology® examined current issues in immunotherapy.
AJMC® in the Press, February 23, 2018
February 23rd 2018

AJMC® in the Press, February 23, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Liquid Biopsy Can Predict Outcomes in Patients With Triple-Negative Breast Cancer, Researchers Say
February 22nd 2018

Liquid Biopsy Can Predict Outcomes in Patients With Triple-Negative Breast Cancer, Researchers Say

Jaime Rosenberg
Cell-free DNA derived from liquid biopsy offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and can predict patient survival outcomes for patients with metastatic triple-negative breast cancer, according to a team of researchers.
Site Logo
February 22nd 2018

With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage

Mary Caffrey
CAR T- cell therapies are among the most expensive ever invented. For now, there’s a lot of uncertainty, as both government and commercial insurers, and a handful of the nation’s leading cancer centers, navigate a reimbursement structure that truly has no precedent.
Site Logo
February 22nd 2018

Diminished Employment Participation After Breast Cancer Linked to Race and Insurance Status

Kelly Davio
African American patients and uninsured patients are more likely to have diminished employment participation 2 years after being cancer free than are those with no history of cancer, according to new research published in Cancer.
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
February 21st 2018

ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit

Jaime Rosenberg
CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.
What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies
February 21st 2018

What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies

AJMC Staff
Research analyzes the cost of processing healthcare bills; supermarket operator Albertsons will buy drugstore chain Rite Aid; a review of phase 1 clinical trials finds just 1 in 10 children with cancer see improvements.
Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
February 21st 2018

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission

Laura Joszt, MA
Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Site Logo
February 21st 2018

Provocative Questions, Better Biomarkers, and the Prospect of Triple Therapy: A Conversation With NYU's Jeffrey S. Weber, MD, PhD

Mary Caffrey
Ipililumumab's role in treating melanoma will change, as the immunotherapy will likely become part of different combinations than we see today.
Site Logo
February 21st 2018

Recent Approval of Trastuzumab Biosimilar, Ogivri, Has Implications for Patients and Industry

Samantha DiGrande
Last year's approval of trastuzumab biosimilar, Ogivri, will be the first competitor to blockbuster drug, Herceptin, for the treatment of HER2-positive breast cancer since its discovery.
Site Logo
February 21st 2018

The Clinical Trial and the Patient's Voice: "I'm Extremely Lucky to Be Alive"

Mary Caffrey
Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care.
Dr Adam Brufsky Discusses Value Coordinates of Breast Cancer Care
February 20th 2018

Dr Adam Brufsky Discusses Value Coordinates of Breast Cancer Care

Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh, notes important value coordinates of breast cancer care.
Site Logo
February 20th 2018

Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer

Dave Nellesen, PhD Katerine Dea, MSc Annie Guerin, MSc Kenneth W. Culver, MD Alex Mutebi, PhD Anand Dalal, MBA, BSPharm
This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.
Cancer Survivors Manage Fatigue With Placebo Pills
February 19th 2018

Cancer Survivors Manage Fatigue With Placebo Pills

Kaitlynn Ely
Cancer survivors may be able to manage the extreme fatigue they experience after treatment by knowingly taking a placebo pill, according to researchers at University of Alabama at Birmingham and Harvard Medical School.
USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women
February 18th 2018

USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women

Jaime Rosenberg
The US Preventive Services Task Force recommends against screening for ovarian cancer in asymptomatic women who are not known to have a high-risk hereditary cancer syndrome because evidence shows that screening does not reduce ovarian cancer mortality.
Site Logo
February 17th 2018

Variation in Markups on Outpatient Oncology Services in the United States

Angela Park Tim Xu, MD, MPP Michael Poku, MD, MBA James Taylor, MBBChir, MPH, MRCS(Eng) Martin A. Makary, MD, MPH
Charges for oncology services vary widely across hospitals and impose financial burdens. Further legislation is needed to address disparities in access to high-quality cancer care.
Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000
February 17th 2018

Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000

Kaitlynn Ely
Merkel cell carcinoma (MCC) is a rare disease, but it's getting less rare. Study results presented at the American Academy of Dermatology 2018 Annual Meeting found that cases of MCC increased 95% between 2000 and 2013
Site Logo
February 17th 2018

eAppendix

Dave Nellesen, PhD Katerine Dea, MSc Annie Guerin, MSc Kenneth W. Culver, MD Alex Mutebi, PhD Anand Dalal, MBA, BSPharm
Site Logo
February 16th 2018

Development of a Tailored Survey to Evaluate a Patient-Centered Initiative

Marcy Winget, PhD Farnoosh Haji-Sheikhi, MS Steve M. Asch, MD, MPH
We developed short patient experience surveys that were sensitive to our broad quality initiative, were meaningful and acceptable to patients, and had good response rates.
AJMC® in the Press, February 16, 2018
February 16th 2018

AJMC® in the Press, February 16, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Roche Acquires Flatiron Health for $1.9 Billion
February 16th 2018

Roche Acquires Flatiron Health for $1.9 Billion

Mary Caffrey
Flatiron Health expects to maintain its current business model in the transaction.
Nat Turner on the Main Barriers for Flatiron Health in Providing Care in Oncology
February 16th 2018

Nat Turner on the Main Barriers for Flatiron Health in Providing Care in Oncology

Nat Turner, co-founder and CEO of Flatiron Health, says that clinical research accessibility is one of the biggest barriers in oncology care that Flatiron Health is working to remove.
Site Logo
February 15th 2018

Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?

Inmaculada Hernandez, PharmD, PhD Samuel W. Bott, BS Anish S. Patel, BS Collin G. Wolf, BS Alexa R. Hospodar, BS Shivani Sampathkumar, BS William H. Shrank, MD, MSHS
The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
Family History Associated With Breast Cancer Risk for Women 65 and Older
February 15th 2018

Family History Associated With Breast Cancer Risk for Women 65 and Older

Jaime Rosenberg
First-degree family history was associated with an increased risk of breast cancer among women aged 65 and older, and risk associated with family history was not significantly modified by breast density, according to a study in JAMA Oncology.
FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer
February 15th 2018

FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer

Laura Joszt, MA
FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years.
<1
...
565758596061626364
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo